A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Docosahexaenoic acid (Primary) ; Soya oil emulsion
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms SCOT
  • Sponsors Sancilio & Company
  • Most Recent Events

    • 26 Jul 2017 Top-line results from the study are expected in early Q4 this year, according to a Sancilio Pharmaceuticals media release.
    • 26 Jul 2017 Status changed from recruiting to active, no longer recruiting, according to a Sancilio Pharmaceuticals media release.
    • 10 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top